Literature DB >> 24889719

Role of pregnane X receptor in chemotherapeutic treatment.

Wei Zhuo1, Lei Hu, Jinfeng Lv, Hongbing Wang, Honghao Zhou, Lan Fan.   

Abstract

Pregnane X receptor (PXR) is a member of the nuclear receptor superfamily that differently expresses not only in human normal tissues but also in numerous types of human cancers. PXR can be activated by many endogenous substances and exogenous chemicals, and thus affects chemotherapeutic effects and intervenes drug-drug interactions by regulating its target genes involving drug metabolism and transportation, cell proliferation and apoptosis, and modulating endobiotic homeostasis. Tissue and context-specific regulation of PXR contributes to diverse effects in the treatment for numerous cancers. Genetic variants of PXR lead to intra- and inter-individual differences in the expression and inducibility of PXR, resulting in different responses to chemotherapy in PXR-positive cancers. The purpose of this review is to summarize and discuss the role of PXR in the metabolism and clearance of anticancer drugs. It is also expected that this review will provide insights into PXR-mediated enhancement for chemotherapeutic treatment, prediction of drug-drug interactions and personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24889719      PMCID: PMC4386062          DOI: 10.1007/s00280-014-2494-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  117 in total

1.  Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines.

Authors:  Rong Huang; Daryl J Murry; Dhanashri Kolwankar; Stephen D Hall; David R Foster
Journal:  Biochem Pharmacol       Date:  2006-04-18       Impact factor: 5.858

Review 2.  Nuclear receptor coactivators and corepressors.

Authors:  K B Horwitz; T A Jackson; D L Bain; J K Richer; G S Takimoto; L Tung
Journal:  Mol Endocrinol       Date:  1996-10

Review 3.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

4.  Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.

Authors:  Wen Xie; Mei-Fei Yeuh; Anna Radominska-Pandya; Simrat P S Saini; Yoichi Negishi; Bobbie Sue Bottroff; Geraldine Y Cabrera; Robert H Tukey; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

5.  Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells.

Authors:  N Ouyang; S Ke; N Eagleton; Y Xie; G Chen; B Laffins; H Yao; B Zhou; Y Tian
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

6.  Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR 1 and PXR 2.

Authors:  Leslie M Tompkins; Tim L Sit; Andrew D Wallace
Journal:  Drug Metab Dispos       Date:  2008-02-14       Impact factor: 3.922

Review 7.  The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.

Authors:  S Harmsen; I Meijerman; J H Beijnen; J H M Schellens
Journal:  Cancer Treat Rev       Date:  2007-04-23       Impact factor: 12.111

8.  Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.

Authors:  Jie Zhou; Maria Febbraio; Taira Wada; Yonggong Zhai; Ramalinga Kuruba; Jinhan He; Jung Hoon Lee; Shaheen Khadem; Songrong Ren; Song Li; Roy L Silverstein; Wen Xie
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

9.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Authors:  J van Asperen; O van Tellingen; A Sparreboom; A H Schinkel; P Borst; W J Nooijen; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.

Authors:  Suman Verma; Michelle M Tabb; Bruce Blumberg
Journal:  BMC Cancer       Date:  2009-01-05       Impact factor: 4.430

View more
  11 in total

1.  miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway.

Authors:  Qing-Ping Shao; Chen Wei; Jie Yang; Wen-Zhou Zhang
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

Review 2.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

3.  Pregnane X Receptor and Cancer: Context-Specificity is Key.

Authors:  Satyanarayana R Pondugula; Petr Pavek; Sridhar Mani
Journal:  Nucl Receptor Res       Date:  2016-06-12

Review 4.  Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk.

Authors:  Peter Oladimeji; Hongmei Cui; Chen Zhang; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-06-23       Impact factor: 4.481

5.  Pregnane X receptor expression in skin: the good and the bad.

Authors:  Daniel D Bikle
Journal:  Exp Dermatol       Date:  2015-09-15       Impact factor: 3.960

6.  The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.

Authors:  Noor Safwah Damanhuri; Endang Kumolosasi; Marhanis Salihah Omar; Amirul Faiz Abd Razak; Ahmad Hasnan Mansor
Journal:  Daru       Date:  2021-01-06       Impact factor: 3.117

7.  Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library.

Authors:  Caitlin Lynch; Srilatha Sakamuru; Ruili Huang; Jake Niebler; Stephen S Ferguson; Menghang Xia
Journal:  Biochem Pharmacol       Date:  2020-12-14       Impact factor: 6.100

8.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20

Review 9.  PXR variants: the impact on drug metabolism and therapeutic responses.

Authors:  C Trent Brewer; Taosheng Chen
Journal:  Acta Pharm Sin B       Date:  2016-07-27       Impact factor: 11.413

10.  Glucose-dependent regulation of pregnane X receptor is modulated by AMP-activated protein kinase.

Authors:  Peter O Oladimeji; Wenwei Lin; C Trent Brewer; Taosheng Chen
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.